Galapagos

Generaal De Wittelaan L 11A3
2800 Mechelen
BE
Galapagos
Foundation date
30/06/1999
Sector
#Biotechnology - TherapeuticsSubsector
Therapeutic areas
- #Diseases of the blood and blood-forming organs - immune disorders
- #Infectious and parasitic diseases
- #Musculoskeletal system and connective tissue
- #Neoplasms / cancer / oncology
- #Respiratory system
Galapagos seeks to develop a robust portfolio of clinical-stage breakthrough therapies that have the potential to revolutionize existing treatment paradigms. Our ambition is to become a leading global biotechnological company, focused on the development and commercialization of novel medicines that will improve people’s lives.
Upcoming events
All events-
0106 '23
KNOWLEDGE FOR GROWTH 2023
Event by: flanders.bio -
0506 '23
BIO International Convention 2023
Event by: Biotechnology Innovation Organisation -
2206 '23
Translational Research in Crops
Event by: VIB
Latest news
More news-
Mithra appoints experienced life sciences executive Christian Homsy* as Chairman
18 hours ago
Read more
-
Oxurion reaches enrollment target in KALAHARI Phase 2, Part B trial of novel PKal inhibitor THR-149 in diabetic macular edema
Friday May 26th 2023
Read more
-
How garbage disposal clogs in cells can lead to Alzheimer’s
Friday May 26th 2023
Read more
Jobs
More jobs-
30/05/23
Remote, Brussels, Abroad
Executive, Chief Financial Officer - European Operations
Permanent, Freelance
General Inception -
-